Psychoactive Synthetic Adulterants in Tablets Sold as MDMA after the COVID-19 Pandemic: Implications for Central Effects.
Current Neuropharmacology January 9, 2026 Maria Antonietta De Luca, Cristina Miliano, Amanda Roxburgh et al. 1 citation
Preclinical and clinical studies reported that 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') can cause adverse effects in the central nervous system (CNS). Recently, preclinical studies have demonstrated that certain psychoactive substances may exacerbate the noxious central effects of MDMA when co-administered, including substances that are contained as adulterants in tablets sold as...